FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer’s disease

FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer’s disease

Abstract Background Neurofibrillary pathology composed of tau protein is closely correlated with severity and phenotype of cognitive impairment in patients with Alzheimer’s disease and non-Alzheimer’s tauopathies. Targeting pathological tau proteins via immunotherapy is a promising strategy for dise...

Full description

Bibliographic Details
Main Authors: Petr Novak, Reinhold Schmidt, Eva Kontsekova, Branislav Kovacech, Tomas Smolek, Stanislav Katina, Lubica Fialova, Michal Prcina, Vojtech Parrak, Peter Dal-Bianco, Martin Brunner, Wolfgang Staffen, Michael Rainer, Matej Ondrus, Stefan Ropele, Miroslav Smisek, Roman Sivak, Norbert Zilka, Bengt Winblad, Michal Novak
Format: Article
Language:English
Published: BMC 2018-10-01
Series:Alzheimer’s Research & Therapy
Subjects:
Tau
Alzheimer’s disease
Vaccine
Immunotherapy
Active immunotherapy
Clinical trial
Online Access:http://link.springer.com/article/10.1186/s13195-018-0436-1

Similar Items

Similar Items